|
Post by mymann on Aug 9, 2022 0:23:41 GMT -5
"Anyone care to speculate on the -.18 [-4.14%] drop after hours?? Just wondering........." "IMHO, unless there is big volume based on real news, every reason to stay away from PM & AF… fools & players." Hence, WHY, I have to ask stupid questions...Thanks for the enlightenment! Always learning from you all! Onward and upward MNKD!!! No worries. The last after hours trade was a grand total of one share traded at $4.14. The prior trade was also one share traded at $4.40. These are stupid games that have no relationship to what happens the following day. You can see all trades at the Nasdaq site. I had no knowledge in stock investing and jumped into Mnkd 13 years ago and proboards Members have taught me so much about investing and market behavior on my Mnkd investment that I thank you fellow members on mnkd keeping me updated on our dream.
|
|
|
Post by prcgorman2 on Aug 9, 2022 9:53:24 GMT -5
Down .21 on very light volume on same day as 2nd quarter earnings report. Interesting.
|
|
|
Post by akemp3000 on Aug 9, 2022 10:23:03 GMT -5
It must be due to all the bad news about Mannkind lately...yes, being facetious! Seriously though, this company should no longer be trading as a penny stock...meaning under $5. Hopefully, the absurdity ends very soon.
|
|
|
Post by ktim on Aug 9, 2022 11:53:40 GMT -5
It must be due to all the bad news about Mannkind lately...yes, being facetious! Seriously though, this company should no longer be trading as a penny stock...meaning under $5. Hopefully, the absurdity ends very soon. It's a billion dollar company. That's well on its way to being considered mid-cap. A bit of a technicality of share count that it trades under $5.
|
|
|
Post by Chris-C on Aug 9, 2022 13:10:14 GMT -5
Down .21 on very light volume on same day as 2nd quarter earnings report. Interesting. Not coincidental, methinks. It is the MNKD way. This may be the most peculiar stock on the NASDAQ. The market does not anticipate good news, because frankly, the stock has over-promised and under-delivered for most of its existence. All in my opinion, of course.
I'm still long and strong, looking at it as (yet) another buying opportunity. Plus, there is a belief that "good news" earnings reports are delivered before the bell, not after. I'm not sure if that has ever been examined objectively though (actually, I'm pretty sure it has) but I don't have a link to support my supposition.
Anyone?
GLTAL
|
|
|
Post by RainbowUnicorn on Aug 9, 2022 13:25:43 GMT -5
Down .21 on very light volume on same day as 2nd quarter earnings report. Interesting. Not coincidental, methinks. It is the MNKD way. This may be the most peculiar stock on the NASDAQ. The market does not anticipate good news, because frankly, the stock has over-promised and under-delivered for most of its existence. All in my opinion, of course.
I'm still long and strong, looking at it as (yet) another buying opportunity. Plus, there is a belief that "good news" earnings reports are delivered before the bell, not after. I'm not sure if that has ever been examined objectively though (actually, I'm pretty sure it has) but I don't have a link to support my supposition.
Anyone?
GLTAL
I have to concur. The market is snake bit. I believe in the products and the company, a little more patience is all that is required. Due diligence, ongoing research, and Institutional investment support this belief. Share price, not so much.
|
|
|
Post by peppy on Aug 9, 2022 13:52:09 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 9, 2022 13:59:02 GMT -5
I bet you'll take to that, like a duck to water.....
|
|
|
Post by peppy on Aug 9, 2022 14:01:26 GMT -5
I bet you'll take to that, like a duck to water..... please state what "That" is. I am a very strong swimmer.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 9, 2022 14:15:21 GMT -5
I bet you'll take to that, like a duck to water..... please state what "That" is. I am a very strong swimmer. With an earnings surprise!
|
|
|
Post by boytroy88 on Aug 9, 2022 15:05:48 GMT -5
Looks like loss of .11/shr vs .9 expected....
|
|
|
Post by RainbowUnicorn on Aug 9, 2022 15:10:32 GMT -5
Let the games begin. Talk about some kinda snake bit, including venom induced psychedelia... I was hemming and hawing, weighing my options, waiting to make a move or not, and rolling the dice. Had some issues with my online purchase order. Finally went with a 20k limit order at $4.13, but we were already up to $4.20. My bad, what, added 20,000 shares. What a close.
|
|
|
Post by peppy on Aug 9, 2022 15:12:54 GMT -5
Looks like loss of .11/shr vs .9 expected.... investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2022-second-quarter-financialTotal revenues were $18.9 million for the second quarter of 2022, reflecting Afrezza® net revenue of $10.6 million, V-Go net revenue of $2.1 million, collaborations and services revenue of $5.9 million, and royalties of $0.3 million. Afrezza net revenue increased 7% compared to $10.0 million in the second quarter of 2021 as a result of increased price, which included more favorable gross-to-net deductions, and patient demand which was substantially offset by wholesaler inventory ordering patterns that resulted in lower inventory levels for the second quarter of 2022. Collaborations and services revenue decreased $7.4 million compared to the second quarter of 2021 primarily due to the completion of the R&D Services associated with our collaboration with United Therapeutics (“UT”) in the second half of 2021. In August 2021, we entered into a commercial supply agreement (“CSA”) with UT. Revenue associated with the CSA was deferred until commercial product was manufactured and sold to UT, which occurred in the second quarter of 2022 when $4.7 million of revenue was recognized. The deferred revenue balance associated with the CSA increased by $4.1 million in the second quarter to $29.8 million as of June 30, 2022.
|
|
|
Post by biffn on Aug 9, 2022 15:20:13 GMT -5
20% beat on revenue.
|
|
|
Post by peppy on Aug 9, 2022 15:31:11 GMT -5
From markado on another thread. Interesting that neither the reported revenue nor the eps account for the $30M in Tyvaso Dpi that is still sitting in deferred revenue, but is all but guaranteed to be received from UTHR. Assuming a conservative mfg margin of 40%,that revenue is worth $12M to the bottom line. That's another $.05 in eps, which, if imbued into today's report would put us at -.06 per share or a 33% beat on EPS. Mike and crew need to learn to factor receivables and recognize revenue or paint the picture as acurately but as brightly as feasible (and legal to do so).
|
|